The Trump administration will hold off on imposing pharmaceutical tariffs Oct. 1 for companies that do not onshore manufacturing or participate in the president’s “Most Favored Nations” pricing initiative, a White House official told Becker’s. The move marks a departure from President Trump’s original Sept. 25 threat to impose a 100% tariff on branded drug imports from manufacturers without U.S. production facilities, effective Oct. 1.

White House officials pointed to remarks from Commerce Secretary Howard Lutnick during a Sept. 30 Oval Office briefing, wherein Pfizer announced it would lower U.S. drug prices. At the event, Mr. Lutnick said the administration was “going to let [the talks] play out and finish these negotiations, because they are the most important thing to the American peo

See Full Page